Lior Shaltiel
Vorstandsvorsitzender bei NUREXONE BIOLOGIC INC.
Vermögen: - $ am 30.04.2024
Profil
Dr. Lior Shaltiel is a Chief Executive Officer & Director at NurExone Biologic Ltd.
and a Chief Executive Officer & Director at NurExone Biologic, Inc. He is on the Board of Directors at NurExone Biologic Ltd.
and NurExone Biologic, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NUREXONE BIOLOGIC INC
-.--% | 08.05.2023 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Lior Shaltiel
| Unternehmen | Position | Beginn |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Vorstandsvorsitzender | 01.04.2021 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Vorstandsvorsitzender | 01.04.2021 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NUREXONE BIOLOGIC INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Health Technology |
